01/21/2026

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Agios’ AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia

FDA Approves Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) for a First-Line Combination Regimen when Combined with LAZCLUZE (lazertinib)

More Info